ArticlePloS one2026
Epidemiology of human RSV in Taiwan, 2018-2024.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in infants and older adults worldwide. This retrospective study investigated the epidemiology and molecular characteristics of RSV in Taiwan from 2018 to 2024 using data from the National Community Virus Surveillance System, which encompassed the coronavirus disease 2019 (COVID-19) pandemic period. Among 74,773 samples collected from patients with suspected respiratory viral infections, 1,224 samples tested positive for RSV, yielding an overall detection rate of 1.6%. RSV circulation was markedly disrupted during the COVID-19 pandemic, with no cases being detected during periods of stringent public health interventions and delayed outbreaks observed in late 2020 and 2023. Following the relaxation of nonpharmaceutical interventions, RSV seasonality shifted, with altered epidemic timing and changes in age distribution being observed. Most infections occurred in children younger than 5 years of age (92.6%), and RSV positivity varied significantly across age groups but not between sexes. Among the 1,224 isolates, 463 were randomly selected for glycoprotein (G) gene sequencing. The results revealed that RSV-A accounted for the majority (81.6%) of the tested isolates and were clustered within the A.D lineage, with A.D.3 being the dominant clade. The remaining strains were determined to be RSV-B, which were classified within the B.D lineage, with B.D.E.1 being observed as the dominant clade. The emergence of multiple RSV subclades during the study period indicates ongoing viral evolution in Taiwan. These findings demonstrate substantial shifts in RSV epidemiology following the COVID-19 pandemic and highlight viral evolution and clade replacement. Continued molecular surveillance is essential to monitor epidemiological trends and inform vaccination and prevention strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.